BIOCRYST PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year Five
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Long-Term Debt, Maturity, Year Five of $1.00 million as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2018-11-08
- 2018-09-30: Long-Term Debt, Maturity, Year Five $1.00M.
- 2017-12-31: Long-Term Debt, Maturity, Year Five $2.30M.
- 2017-09-30: Long-Term Debt, Maturity, Year Five $2.30M.
- 2017-06-30: Long-Term Debt, Maturity, Year Five $2.30M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2018-09-30 | $1.00M 10-Q · filed 2018-11-08 |
| 2017-12-31 | $2.30M 10-K · filed 2018-03-12 |
| 2017-09-30 | $2.30M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $2.30M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.30M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $2.30M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |